URGN
UroGen Pharma Ltd.
NASDAQ · Healthcare · Biotechnology · US
$44.09
−1.76%Aug 20, 2026, 11:00 UTC
UroGen Pharma entered into a strategic collaboration and investment agreement with IntraGel to access its biodegradable sustained-release gel platform and expand its oncology pipeline.
Aug 5, 2026, 00:00 UTC
UroGen Pharma Ltd. reported its Q2 2026 financial results, with total revenue of $72.5 million and a net loss of $14.4 million.
Jul 8, 2026, 12:00 UTC
UroGen Pharma received FDA clearance of its Investigational New Drug application for UGN-501, an investigational oncolytic virus for non-muscle invasive bladder cancer.
Source: